Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| AstraZeneca | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators will look at the short- (in hospital) and long- term ( 1 year)outcome in consecutive patients who undergo stent implantation and angioplasty in Jordan.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PCI patients | Patients undergoing PCI for elective or ACS will be enrolled. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Procedure: PCI | Procedure |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Cardiovascular mortality | All cases of deaths from cardiovascular causes will be counted at 1 year. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Admission for urgent coronary revascularization | All events of hospital readmission for repeat coronary intervention for acute coronary syndrome from the time of discharge from hospital up to 1 year will be documented. | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Stent thrombosis | All cases of definite/probable/possible stent thrombosis will be documented from the time of stent implantation during the index admission to 1 year. | 1 year |
| Baseline risk factors and outcome after 1 year |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Consecutive patients with acute coronary syndrome and stable coronary syndromes undergoing PCI.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Istishari Hospital | Amman | 11954 | Jordan |
Not provided
| Label | URL |
|---|---|
| JCC group websites describes the studies done by the JCC Group | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D004304 | Dosage Forms |
| ID | Term |
|---|---|
| D004364 | Pharmaceutical Preparations |
| D013678 | Technology, Pharmaceutical |
| D008919 | Investigative Techniques |
Not provided
Not provided
Not provided
Not provided
Not provided
Several factors at baseline will be evaluated as potential contributors to adverse outcome after one year, including: age, gender, renal impairment, heart failure, CRUSADE bleeding risc score, GRACE risk score, diabetes, multiple risk factors, BMI, and smoking.
| 1 year |
| Adherence to guidelines in patients undergoing PCI | Using medications (statins, antiplatelets, ACI inhibitors/ARBs, B blockers, etc),and diagnostic and interventional procedures, and reaching target parameters (LDL cholesterol and HbA1c) according to the published guidelines will be evaluated. | 1 year |